Amendments to the Claims:

The listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claim 1 (original):

A compound having the structure:



wherein R_1 is $-OCH_3$ or OH;

wherein R_2 is $-CH_2OH$, $-CH_2OCH_3$, or -COOH;

wherein R_1 and R_2 together form a 5-membered lactone ring;

wherein R_3 is selected from the group consisting of

$-(CH_2)_3OH$,


,


,


,


,


,


,


,

and


;

provided that when R_1 is OH, R_3 cannot be


;

or a pharmaceutically acceptable salt thereof.

Claim 2 (original): The (-) enantiomer of the compound of claim 1.

Claim 3 (original): The (+) enantiomer of the compound of claim 1.

Claims 4-14 (canceled).

Claim 15 (currently amended): A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1, ~~6, 8, 9, 12, 13, or 14~~ and a pharmaceutically acceptable carrier.

Claim 16 (original): The pharmaceutical composition of claim 15, wherein the therapeutically effective amount is an amount from about 0.01 mg to about 500 mg.

Claim 17 (original): The pharmaceutical composition of claim 16, wherein the therapeutically effective amount is an amount from about 0.1 mg to about 60 mg.

Claim 18 (original): The pharmaceutical composition of claim 17, wherein the therapeutically effective amount is an amount from about 1 mg to about 30 mg.

Claim 19 (original): The pharmaceutical composition of claim 15, wherein the carrier is a liquid and the composition is a solution.

Claim 20 (original): The pharmaceutical composition of claim 15, wherein the carrier is a solid and the composition is a tablet.

Claim 21 (original): The pharmaceutical composition of claim 15, wherein the carrier is a gel and the composition is a suppository.

Claim 22 (currently amended): A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 ~~or 14~~ effective to treat benign prostatic hyperplasia.

Claim 23 (currently amended): A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 ~~or 14~~ in combination with a 5 alpha-reductase inhibitor effective to treat benign prostatic hyperplasia.

Claim 24 (original): The method of claim 23, wherein the 5-alpha reductase inhibitor is finasteride.

Claim 25 (original): A method of relaxing lower urinary tract tissue which comprises administering to the subject an amount of the compound of claim 1 effective to relax lower urinary tract tissue.

Claim 26 (original): The method of claim 25, wherein the lower urinary tract tissue is urethral smooth muscle.

Claim 27 (currently amended): A method of inhibiting contraction of prostatic tissue in a subject which comprises administering an amount of a compound according to claim 1 ~~or 14~~ effective to inhibit contraction of prostatic tissue.

Claim 28 (currently amended): A method of treating a disease which is susceptible to treatment by antagonism of the α_{1A} receptor which comprises administering an amount of a compound of claim 1 ~~or 14~~ effective to treat the disease.

Claim 29 (currently amended): A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 ~~or 14~~ in combination with therapeutically effective amount of finasteride and a pharmaceutically acceptable carrier.

Claim 30 (original): The pharmaceutical composition of claim 29, wherein the therapeutically effective amount of the compound is an amount from about 0.01 mg to about 500 mg and the therapeutically effective amount of the finasteride is about 5 mg.

Claim 31 (original): The pharmaceutical composition of claim 29, wherein the therapeutically effective amount of the compound is an amount from about 0.1 mg to about 60 mg and the therapeutically effective amount of the finasteride is about 5 mg.

Claim 32 (original): The pharmaceutical composition of claim 29, wherein the therapeutically effective amount of the compound is an amount from about 1 mg to about 30 mg and the therapeutically effective amount of the finasteride is about 5 mg.

Claim 33 (currently amended): A process for making a pharmaceutical composition which comprises combining a therapeutically effective amount of a compound of claim 1 ~~or 14~~ and a pharmaceutically acceptable carrier.